Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences
November 22, 2017 06:00 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results
November 13, 2017 13:30 ET
|
Gemphire Therapeutics Inc.
Gemcabene reduced LDL-C by 20% and hsCRP by 53% when added to moderate intensity statin therapy In cardiometabolic patients gemcabene improves atherogenic burden and reduces inflammation LIVONIA,...
Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017
October 23, 2017 08:00 ET
|
Gemphire Therapeutics Inc.
Data Support Clinical Evaluation of Gemcabene as a Potential Treatment For NAFLD/NASH Clinical Trial in NAFLD/NASH Planned to Begin 4Q-2017 LIVONIA, Mich., Oct. 23, 2017 (GLOBE NEWSWIRE) --...
Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit
September 25, 2017 09:00 ET
|
Gemphire Therapeutics
COBALT-1 results show significant LDL-C lowering for FH patients, including a mean reduction in LDL-C of 39% in the HeFH population Gemcabene demonstrates novel mechanism to significantly lower LDL-C...
Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development
September 19, 2017 16:01 ET
|
Gemphire Therapeutics
New analysis of data shows clinically meaningful reductions in LDL-C and hsCRP across multiple trials and confirms support to advance gemcabene into Phase 3 End of Phase 2 meetings planned for early...
Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York
September 18, 2017 08:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene
September 14, 2017 16:36 ET
|
Gemphire Therapeutics
Company plans to advance gemcabene into Phase 3 development Conference call at 4:30 pm ET on September 19 LIVONIA, Mich., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc....
Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 14, 2017 06:00 ET
|
Gemphire Therapeutics
Gemcabene Successful in Phase 2 COBALT-1 HoFH Trial Gemcabene Hits Primary Endpoint in Phase 2 ROYAL-1 Hypercholesterolemia Trial LIVONIA, Mich., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Gemphire...
Gemphire to Present at the Canaccord Genuity Growth Conference 2017
August 07, 2017 10:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients
August 07, 2017 06:00 ET
|
Gemphire Therapeutics
Gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C Company to host conference call at 8:00 am ET, Monday, August 7, 2017 LIVONIA, Mich., Aug. 07,...